Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced that Astellas Pharma Inc. (TSE: ...

WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies ...

For the millions of people living with genetic diseases like muscular dystrophy and inherited liver disorders, one of the ...

Gene therapy holds potential for treating neurological diseases by delivering genetic information into specific cell types. However, selective and efficient targeting of cell types remains challenging ...

Joseph La Barge has been mulling over the limitations of gene therapy for some time. So, when he left his position at Spark Therapeutics, having watched the company grow from its start in borrowed ...

LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced ...

Adeno-associated virus (AAV) capsids are an effective mechanism for delivering gene therapies intended for therapeutic use. A critical production step is the separation of full capsids from empty ones ...

The first peer-reviewed journal in the field of human gene therapy, providing all-inclusive coverage of the research, methods, and clinical developments that are driving today's explosion of gene ...